4dmedical Ltd. · ASX:4DX
4dmedical — Shareholder Meeting (November 2023)
34 slides from 4dmedical's shareholder meeting presentation, Nov 2, 2023
Slide 1: Presentation and Chairman's address to the 2023 AGM
ASX announcement ASX:4DX Presentation and Chairman's address to the 2023 Annual General Meeting 2 November 2023 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) attaches the following materials to be presented at the Annual General Meeting of Shareholders to be held today at 10.00am AEDT: 1
Slide 2: Chairman's Address
4DMedical Limited Annual General Meeting Chairman’s Address 10.00AM, Thursday, 2 November 2023 Good morning Shareholders and fellow Directors, Welcome to the Annual General Meeting of 4DMedical for the 2022-23 Financial Year. Today we are gathered on the traditional lands of the Wurundjeri peoples o
Slide 3: Chairman's Address (continued)
scan represented a major step forward in demonstrating our ability to deliver an XV LVAS scan in a routine VA hospital clinical setting. Closely following this achievement, we were granted ‘Authority to Operate’ at the Harry S. Truman Memorial Veterans Hospital, which allows us to deliver scans at s
Slide 4: Chairman's Address (conclusion)
During my tenure, it has transitioned from start up to IPO to the productive organisation it has become – benefitting from the application of key governance principles and oversight without detriment to a culture of innovation and a capability to translate research into valuable clinical practices.
Slide 5: The future of lung health - Annual General Meeting
For personal use only The future of lung health 4DMedical Limited (ASX:4DX) Annual General Meeting 2 November 2023 4DMedical Limited ABN 31 161 684 831
Slide 6: Disclaimer
Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as of 2 N
Slide 7: Overview
For personal use only Overview
Slide 8: Agenda
Agenda 1. Opening & introductions For personal use only 2. Chairman’s address 3. CEO address 4. Procedural matters 5. Formal business 6. Closing remarks 4
Slide 9: Board of Directors and Key advisors
Board of Directors Key advisors Significant medical and commercial sector experience Medical experts Dr SAM HUPERT MBBS Advisory Board Member For personal use only Co-founder and Chief Executive Officer of Pro Medicus Ltd (ASX:PME) which develops and markets health imaging software primarily for rad
Slide 10: Chairman's address
Chairman’s address For personal use only BRUCE RATHIE Non-Executive Chairman Experienced lawyer, investment banker and company director.
Slide 11: FY23 financial summary
FY23 financial summary • 4DMedical reported a net cash balance of $69.6m $0.7m For personal use only $69.6 million at 30 June 2023, with zero debt. Cash reserves Sales and maintenance revenue • Total income is $13.9 million, up 3.7%, comprising $0.7 million in operating revenue and $13.2 million in
Slide 12: Chief Executive Officer
Chief Executive Officer For personal use only Dr ANDREAS FOURAS PhD Managing Director Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical’s core technologies.
Slide 13: CEO quote on XV Technology
“4DMedical has all the advantages and none of the disadvantages of existing lung diagnostic technology. For personal use only Our XV Technology® and Lung Ventilation Analysis Software (XV LVAS®) is the latest evolution. The opportunities are significant.” Professor Andreas Fouras Founder, Inventor M
Slide 14: XV Technology advantages
XV Technology® advantages For personal use only New medical insights Improved safety Superior results Functional insight of Comparable radiation High-detail resolution spirometry at a regional level dose to X-ray of a CT scan Patient outcomes Time efficient Low cost Improved clinical Faster, more ef
Slide 15: FY23 achievements 1H FY2023
FY23 achievements 1H FY2023 Commercialisation Early-stage commercialisation in Australia June 2022 Expanded relationship with Australia’s I-MED Radiology Network For personal use only Clinical validation Burn pit trial validates XV Technology® August 2022 Burn pit clinical trial conducted by US-base
Slide 16: FY23 achievements 2H FY2023
FY23 achievements 2H FY2023 Commercialisation Signing of first US hospital SaaS contract April 2023 5-year contract signed with the University of Miami to provide XV LVAS® ventilation reports, its first US hospital SaaS contract For personal use only Commercialisation Dr David Shulkin joins 4DMedica
Slide 17: FY24 achievements to date
FY24 achievements to date 1H FY2024 Government funding 4DMedical wins $1.1m CTCM funding July 2023 Funding enables expansion of XV Scanner capability beyond ventilation into perfusion For personal use only Leadership and Appointment of Geraldine McGinty to Board September expertise Appointment of Ge
Slide 18: FY24 target catalysts
FY24 target catalysts Commercialisation • VA funded trial • 2nd Authority to Operate awarded enabling National Authority to Operate For personal use only • Extend Department of Defense engagement • Execution of commercial agreement with US based academic medical center • Expansion in ANZ Clinical •
Slide 19: Investment opportunity
Investment opportunity Global demand • The demand for sophisticated respiratory diagnostics solutions is growing • Diagnostic technology largely unchanged for ~50 years • Lung diagnostics market ripe for disruption For personal use only Global • Commercialisation driven by clinical utilisation demon
Slide 20: Commercialisation strategy
Commercialisation strategy Clinical trials Commercial pilots Long term agreements Validating efficacy and utility Generating clinical use case Sustainable revenue generation For personal use only Research partners delivering the body Physicians gaining familiarity with Long term agreements with hosp
Slide 21: Software offering & applications
Software offering & applications For personal use only 4DMedical Current product XV LVAS® CT LVAS™ CT:VQ Currently in software offering release (ventilation) (ventilation) (ventilation / perfusion) development Image acquisition modality X-ray XV Scanner CT Existing hospital & 4DMedical hardware util
Slide 22: Commercialisation strategy – clinical trial validation
Commercialisation strategy – clinical trial validation BLVR Asthma Paediatric CF Lung Transplant ILD-WLL University of Miami Cleveland Clinic John Hopkins Alfred Hospital, Melbourne Prince Charles Hospital XV LVAS® XV LVAS® XV LVAS® XV LVAS® XV LVAS® For personal use only Imaging in progress & PH CO
Slide 23: Procedural matters
For personal use only Procedural matters
Slide 24: Formal business
For personal use only Formal business
Slide 25: Items of Business
Items of Business Item 1: Financial Report, Directors’ Report and Auditors Report For personal use only Item 2: Remuneration Report Item 3: Election of Director, Dr Geraldine McGinty Item 4: Withdrawn Item 5: Re-election of Director, Ms Lilian Bianchi Item 6: Grant of Options to the Managing Directo
Slide 26: Item 1: Financial Report, Directors' Report and Auditors Report
Formal business Item 1: Financial Report, Directors’ Report and Auditors Report To receive and consider the Financial Report of the Company and its controlled entities and the For personal use only Reports of the Directors and Auditor for the year ended 30 June 2023. 22
Slide 27: Item 2: Remuneration report
Formal business Item 2: Remuneration report To consider, and if thought fit, to pass, the following as an ordinary resolution: For personal use only “That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2023, is adopted.” In Favour Against Proxy Discretion A
Slide 28: Item 3: Election of Director, Dr Geraldine McGinty
Formal business Item 3: Election of Director, Dr Geraldine McGinty To consider, and if thought fit, to pass, the following as an ordinary resolution: For personal use only “That, for the purposes of clause 13.1 of the Company’s constitution, ASX Listing Rule 14.4, and for all other purposes, Dr Gera
Slide 29: Item 4: Re-election of Director, Mr Bruce Rathie
Formal business Item 4: Re-election of Director, Mr Bruce Rathie Withdrawn For personal use only 25
Slide 30: Item 5: Re-election of Director, Ms Lilian Bianchi
Formal business Item 5: Re-election of Director, Ms Lilian Bianchi To consider, and if thought fit, to pass, the following as an ordinary resolution: For personal use only “That, for the purposes of clause 13.3 of the Company’s constitution, ASX Listing Rule 14.5, and for all other purposes, Ms Lili
Slide 31: Item 6: Grant of Options to the Managing Director and CEO
Formal business Item 6: Grant of Options to the Managing Director and CEO To consider, and if thought fit, to pass, the following as an ordinary resolution: For personal use only “That, for the purposes of ASX Listing Rule 10.4, sections 200B and 200E of the Corporations Act and for all other purpos
Slide 32: Item 7: Amendments to Constitution
Formal business Item 7: Amendments to Constitution To consider, and if thought fit, to pass, the following as a special resolution: For personal use only “That, for the purposes of section 136(2) of the Corporations Act 2001 (Cth) and for all other purposes, the Members of the Company approve the am
Slide 33: Poll
For personal use only Poll
Slide 34: 4DMedical Limited contact details
4DMedical Limited (ASX:4DX) For personal use only Annual General Meeting 2 November 2023 Copyright ©4DMedical Limited 2023 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831